Increasing evidence indicates that the costs of treating CVD-related conditions are higher than those resulting from better prevention, highlighting the importance of the implementation of CVD prevention programmes within the general population. 3 Of the conventional risk factors, blood pressure, cholesterol, blood sugar, tobacco use, diet and exercise are all considered important therapeutic targets in the effort to reduce the impact of heart attack, stroke and other patient-oriented cardiovascular outcomes. Dyslipidaemia is a wellestablished risk factor for developing CVD. Multiple double-blind placebo controlled trials have shown that treatment with HMG-CoA reductase inhibitors (statins) lowers low-density lipoprotein (LDL) cholesterol levels and is extremely effective in reducing cardiovascular events. 4, 5 Hence, statin therapy now constitutes the cornerstone of all major CVD prevention guidelines, and has become the most commonly prescribed class of medication in the United States and Europe. However, statin treatment is accompanied by potential side effects, which could lead to reduced treatment compliance. 6 In addition, the reduced costs for the national health systems obtained with better CVD prevention could be lost in the case of indiscriminate prescription of statins, extending to patients at very low risk of cardiovascular events. 7 Thus, the identification of patients who could have the greatest benefits from treatment is crucial to reduce the number of people exposed to unnecessary statin treatment harms and costs. Since 2013, the following five organisations have published major guidelines or statements on statins for primary prevention of CVDs: the American College of Cardiology/American Heart Association (ACC/AHA) in 2013; 8 the United Kingdom's National Institute for Health and Care Excellence (NICE) in 2014; 9 and in 2016, the Canadian Cardiovascular Society (CCS); 10 the US Preventive Services Task Force (USPSTF) 11 and the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS). 12 While founded on the same evidence, the five guidelines have substantial differences, including in the recommended prediction model for CVDs, the threshold of CVD risk and LDL-cholesterol levels for assignment of statin use. 13 In this issue of the European Journal of Preventive Cardiology, Schonmann et al. validated the use of the USPSTF recommendations for the initiation of statin treatment in a large Israeli population, also comparing the performance of these guidelines with the ACC/ AHA recommendations.
14 Using a retrospective analysis of electronic health record data routinely collected in the region of Tel Aviv by the largest national health insurance registry in Israel, they showed that implementation of the USPSTF recommendations resulted in a 26% reduction in patients newly eligible for statin treatment compared with the ACC/AHA guidelines. In addition, the authors found that implementation of the pooled cohort equations (PCE; suggested by the ACC/AHA guidelines to assess CVD risk in healthy adults) in the Israeli population resulted in good calibration, with a tendency to underestimate the CVD risk. The recommended treatment thresholds provided excellent calibration for both USPSTF and ACC/AHA recommendations. Finally, the USPSTF guidelines showed an overall negligible net reclassification for the detection of outcome events against the ACC/ AHA recommendations. Based on these results, the authors concluded that calibration, discrimination and net reclassifications were very similar for both recommendations and that application of the USPSTF recommendations could reduce overtreatment with statins in the Israeli population.
The study has several strengths, including a large sample size, the availability of multiple variables by which the authors could obtain a precise estimate of Department of Clinical and Experimental Medicine, University of Pisa, Italy the individual's CVD risk and the availability of outcome data spanning across 10 years. The most important contribution of this report, however, lies in the use of electronic health records obtained from insurance registries that are likely to be representative of the characteristics of the Israeli population. Current guidelines are based on accurate reviews of the literature reporting the impact of statin treatment in patients at risk of CVDs. However, the populations recruited in clinical trials hardly reflect the characteristics of the general population, and this often results in a difficult translation of their recommendations into clinical practice. Thus studies of calibration and efficacy like this have the important merit of translating guideline recommendations into real life, providing the clinician with more solid instruments to assist daily clinical decisions. This is particularly important when facing the decision of initiating statin treatment, as different recommendations are given by the ACC/AHA and USPSTF guidelines. 13 The 2013 ACC/AHA guideline recommended treatment with statins for four categories of individuals: (a) secondary prevention for those with established atherosclerotic cardiovascular disease (ASCVD); (b) primary prevention of ASCVD for those with LDL-cholesterol of 190 mg/dL or greater; (c) primary prevention of ASCVD for individuals with diabetes mellitus and LDL-cholesterol of 70-189 mg/dL; and (d) primary prevention of ASCVD for those without diabetes, with LDL-cholesterol of 70-189 mg/dL, but with an estimated 10-year absolute risk of 7.5% or greater as assessed by the PCE. 8 The 2016 USPSTF guidelines, by contrast, recommended low to moderate dose statins when patients meet all of the following criteria: (a) aged 40-75 years; (b) one or more CVD risk factors (i.e. dyslipidaemia, diabetes, hypertension or smoking); and (c) a calculated 10-year CVD event risk of 10% or greater. 11 Identification of the guideline that best applies to the characteristics of a specific population is important as it provides clinicians practising in a specific country with clear indications on how to optimise CVD prevention.
Nevertheless, the study by Schonmann et al. 14 also has some limitations. While the authors had a significant amount of data to perform the analyses, they decided to use only the data collected within the Tel Aviv area, including only observations with enough information. Thus the validity of the results depends on the representativeness of the selected sample of the wider Israeli population. Also, the authors only explored the performance of two US guidelines and did not include European (ESC/EAS) guidelines in their comparison. Previous reports, instead, provided a much larger comparison, including all available guidelines. 15 The reason for this selection remains unclear although the relatively old age of the studied population might represent a potential explanation, as many subjects could be excluded from the analyses in the attempt to accommodate the age limits of the ESC/ EAS guidelines (40-65 years). 12 The old age of the population might also account for its relatively high CVD risk, with a mean predicted 10-year CVD risk of 12.2% for all participants and 10.5% for the statin-naive patients. This might also explain why in this report PCE seems to underestimate the risk, while overestimation of risk has been reported in other reports using data from the Multi-Ethnic Study of Atherosclerosis (MESA) and Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohorts, and with updated data from ARIC and FHS. 16 Current guidelines tend to overestimate the risk of CVD in old subjects while they do not identify correctly young patients at increased risk because of the heavy influence of chronological age on the 10-year CVD risk calculator used in the PCE. 16 This is an important shortcoming because it has been shown that the lifespan gain from primary prevention interventions is greater in younger patients, 17 and the positive effect of statin treatment in medium and low-risk patients has already been documented. 18, 19 Given that half of all CVD events in men and one-third in women occur before the age of 65 years, 20 reliance on 10-year ASCVD risk alone may miss many younger individuals who could potentially benefit from long-term statin therapy. Therefore, approaches that are independent of chronological age, such as estimating 'cardiovascular age' or 'lifetime risk' have been proposed as appealing alternatives, because primary prevention of ASCVD based on life course rather than 10-years risk prediction models should represent the ultimate aim. Reflecting this concept, the PCE provides an estimated lifetime risk for individuals 20-59 years of age, and the 2012 CCS guidelines endorse the use of heart age in clinical decision-making. However, the report by Schonmann et al.
14 did not test the validity of these approaches to estimate CVD risk in the younger subjects of their population, and this might have led to an overestimation of the CVD risk.
In conclusion, understanding the population effect of the statin guidelines is important and the study by Schonmann et al. 14 supports Israeli clinicians in adopting the correct decision with regard to the initiation of statin treatment. It also highlights potential limitations in current US guidelines, stimulating researchers to test the efficacy of novel approaches based on lifetime risk estimates for better identification of younger subjects at risk of CVD who would benefit from statin treatment.
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